Studies associated with ontology term
VT:0010487   'response to xenobiotic stimulus trait'
   
Navigate ontologies  


Filter by:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
Ackerman1 study archive
with methacholine
Lung, respiratory function, baseline and methacholine-challenged (several doses). QTL population f 7-8wks 2005
Berndt1 ventilator
with methacholine
Airway resistance. Baseline vs. methacholine-challenged (several doses). inbred   (37) both 9-12wks 2010
Berndt2 plethysmography
with methacholine
Lung, respiratory function. Baseline vs. methacholine-challenged (several doses). inbred   (29) both 9-12wks 2010
Berndt2 ventilator
with methacholine
Lung, respiratory function. Anesthetized forced oscillation. Baseline vs. methacholine-challenged (several doses). inbred   (29) both 9-12wks 2010
Bubier3 monitoring system
with morphine
Induced respiratory depression, time to recovery (for mice that survived), survival data (for mice that did not survive). inbred w/CC8   (8) both 2020
Chesler6 study archive
with ethanol
Sensitivity to ethanol. Baseline and ethanol. QTL population both 9-34wks 2012
Crabbe1 balance beam
with ethanol
Ethanol i.p. (several doses) vs. control (saline). Missteps count. 3 beam lengths. inbred   (8) both 8wks 2003
Crabbe1 grid test
with ethanol
Ethanol injection (several doses) vs. control (saline). Grid habituation, missteps rate. inbred   (8) both 8wks 2003
Crabbe2 rotarod
with diazepam
Latency to fall from 5 rpm rotarod immediately after diazepam injection. inbred   (15) both 6-7wks 1998
Crabbe2 drug and metabolite quantification
with diazepam
Diazepam (and metabolite) concentration in brain tissue immediately after diazepam injection and rotarod. inbred   (15) both 6-7wks 1998
Crabbe2 monitoring system
with diazepam
Locomotor activity. Baseline vs. immediately after Diazepam injection (several doses). 15 min test. inbred   (15) both 6-7wks 1998
Crabbe2 body temperature
with diazepam
Baseline vs. 30 min after diazepam injection (several doses). inbred   (15) both 6-7wks 1998
Crabbe3 rotarod
with ethanol
Baseline and ethanol i.p. 3 fixed speeds (several doses) and accelerating. inbred   (22) both 9-17wks 2003
Crabbe4 dowel balance test
with ethanol
Latency to fall 0 min and 30 min post-injection, 2 widths. Ethanol 2 g/kg. inbred   (21) both 9-17wks 2003
Crabbe4 vertical wire mesh
with ethanol
Latency to fall 30 min post-injection. Ethanol 2 g/kg i.p. inbred   (21) both 9-17wks 2003
Crabbe4 grip strength
with ethanol
Baseline vs. 30 min after ethanol 2 g/kg i.p. inbred   (21) both 9-17wks 2003
Crabbe5 parallel rod floor test
with ethanol
Parallel rod balance test, baseline vs. ethanol 2 g/kg i.p.. inbred   (8) both 7-14wks 2005
Crowley1 body weight
with haloperidol
Baseline vs. after haloperidol 60d implant. inbred w/CC8   (27) m 9-28wks 2012
Crowley1 drug and metabolite quantification
with haloperidol
Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Crowley1 inclined screen test
with haloperidol
Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Crowley1 open field test
with haloperidol
Locomotor activity, exploratory behavior, involuntary movement. Baseline vs. haloperidol 60d implant (several timepoints). 60 min test. inbred w/CC8   (27) m 9-28wks 2012
Crowley1 behavior observation
with haloperidol
Observed involuntary repetitive movement. Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
CSNA03 open field test
with cocaine
Distance traveled, habituation ratio, number of rears, ambulatory time, time in perimeter, corners, and center; cocaine sensitization. CC w/CC8   (61) both 4-25wks 2021
CSNA03 operant conditioning chamber
with cocaine
Number of infusions, active lever presses, inactive lever presses, intravenous self administration, reversal learning. CC w/CC8   (61) both 4-25wks 2021
Finn1 bottle choice test
with ethanol
Voluntary consumption of ethanol, and ethanol with saccharin (several doses in water). inbred   (22) both 8-12wks 2007
Frankel1 electroconvulsion test
with lamotrigine
Electroconvulsive thresholds. Lamotrigine. 2 test sites. inbred   (16) both 6-11wks 2000
Gershenfeld1 tail suspension test
with imipramine
Immobility. Baseline (saline) vs. imipramine i.p. 6 min test. inbred   (12) m 5-10wks 2003
Gershenfeld1 light-dark box
with imipramine
Anxiety-related behavior. Baseline (saline) vs. imipramine i.p. 10 min test. inbred   (12) m 5-10wks 2003
Gershenfeld1 open field test
with imipramine
Locomotor activity, exploratory and anxiety-related behavior. Baseline (saline) vs. imipramine i.p. inbred   (12) m 5-10wks 2003
Gould1 forced swim test
with lithium
Lithium (several doses) vs. control. 6 min test. inbred   (11) m 7-8wks 2011
Gould1 drug and metabolite quantification
with lithium
Lithium concentration in brain tissue and blood serum after lithium (several doses). inbred   (11) m 7-8wks 2011
Gould2 drug and metabolite quantification
with nicotine
Amount of nicotine and cotinine in blood plasma after nicotine doses. High and lower doses. inbred   (8) m 8-12wks 2011
Gould2 behavior observation
with nicotine
Observed measures of anxiety. Nicotine (high dose) vs. control. 20 min period. inbred   (8) m 8-12wks 2011
Gould2 elevated plus maze
with nicotine
Measures of anxiety. Nicotine (high dose) vs. control. 5 min test. inbred   (8) m 8-12wks 2011
Gould2 fear conditioning test
with nicotine
Contextual fear, cued fear. Nicotine (high and several lower doses) vs. control. inbred   (8) m 8-12wks 2011
Gould3 behavior observation
with nicotine
Observed measures of anxiety during nicotine withdrawal. Nicotine (several high doses) vs. control. inbred   (8) m 8-12wks 2011
Gould3 elevated plus maze
with nicotine
Measures of anxiety during nicotine withdrawal. Nicotine (several high doses) vs. control. inbred   (8) m 8-12wks 2011
Gould3 fear conditioning test
with nicotine
Contextual fear, cued fear during nicotine withdrawal. Nicotine (high and several lower doses) vs. control. inbred   (8) m 8-12wks 2011
Gould4 conditioned place preference test
with nicotine
Nicotine preference and learning effect. Nicotine-treated vs. control. 2 trials (day 5, day 10). inbred   (8) m 8-10wks 2014
Graubert1 histopathology
with ENU
Tumor growth frequency rates. ENU mutagen 100 mg/kg vs. control. inbred   (20) both 9wks; 12-64wks 2006
Harrill1 body weight
with isoniazid
Body weight. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 organ weights
with isoniazid
Body, liver, kidney weights. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 metabolic panel
with isoniazid
Alanine transaminase. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 lipid profile
with isoniazid
Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 histopathology
with isoniazid
Liver pathology scores. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill2 body weight
with DB289
DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 metabolic panel
with DB289
Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 urinalysis
with DB289
Urine volume, creatinine. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 organ weights
with DB289
Kidney and liver weights. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 biomarker quantification
with DB289
Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 drug and metabolite quantification
with DB289
Kidney metabolite (DB75) concentration. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Jentsch2 operant conditioning chamber
with cocaine
Intravenous self-administration of cocaine via activation of levers, and locomotor activity. BXD   (4) both 8-17wks 2013
Klaassen1 histopathology
with cadmium
Cadmium-induced toxicity to liver, testis, trigeminal ganglia. inbred   (8) m 8wks 2001
Kumar1 study archive
with cocaine
Open field test. Locomotor, anxiety-related, circadian behavior. Baseline and after cocaine i.p. QTL population both 10-14wks 2014
Maurer1 body weight
with atenolol, isoproterenol
Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 organ weights
with atenolol, isoproterenol
Heart, atria, ventricle weights. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 tail cuff
with atenolol, isoproterenol
Heart rate and blood pressure. Conscious mice. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 ECG
with atenolol, isoproterenol
Heart rate and wave amplitudes and intervals. Unconscious. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Metten1 behavior observation
with ethanol
Observed gait, hindlimb splay 10 min and 30 min after ethanol i.p. (several doses). inbred   (9) both 8-11wks 2004
Metten1 open field test
with ethanol
Locomotor activity. Ethanol i.p. (several doses) vs. control (saline i.p.). 45s test. inbred   (9) both 8-11wks 2004
Metten2 behavior observation
with ethanol
Ethanol withdrawal severity and handling-induced convulsions. inbred   (15) m 8-11wks 2005
Palmer2 open field test
with methamphetamine
Locomotor activity and habituation. Baseline (saline) vs. methamphetamine 2 mg/kg i.p. 30 min test. B6.A consomic w/par   (21) both 10wks 2008
Rusyn2 metabolic panel
with trichloroethylene
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum). Baseline and trichloroethylene-exposed (several timepoints). No fast. inbred   (17) m 7wks 2010
Rusyn2 drug and metabolite quantification
with trichloroethylene
Trichloroethylene metabolites in serum, 2h, 4h, 24h after trichoroethylene exposure. inbred   (17) m 7wks 2010
Rusyn5 metabolic panel
with high-fat diet and ethanol
Alanine transaminase (serum) after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. inbred   (14) m 8-14wks 2011
Rusyn5 alcohol quantification
with high-fat diet and ethanol
Alcohol concentration in blood and urine after 4 wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. inbred   (14) m 8-14wks 2011
Rusyn5 organ weights
with high-fat diet and ethanol
Liver weight after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. inbred   (14) m 8-14wks 2011
Rusyn5 histopathology
with high-fat diet and ethanol
Liver histopathology, injury after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. inbred   (14) m 8-14wks 2011
Rusyn5 metabolite quantification
with high-fat diet and ethanol
Homocysteine concentration after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. inbred   (14) m 8-14wks 2011
Rusyn5 lipid profile
with high-fat diet and ethanol
Hepatic triglycerides after 4wk regimen of ethanol and high-fat diet. 24h fast. inbred   (14) m 8-14wks 2011
Rusyn5 RNA expression profiling
with high-fat diet and ethanol
Liver gene expression after 4wk regimen of ethanol and high-fat diet. 24h fast. mRNA abundance relative to the control (high-fat only) group. inbred   (14) m 8-14wks 2011
Rusyn6 organ weights
with trichloroethylene
Liver, kidney weights. Trichloroethylene-exposed vs. control. inbred   (7) m 6-7wks 2014
Rusyn6 metabolic panel
with trichloroethylene
Blood urea nitrogen (serum). Trichloroethylene-exposed vs. control. inbred   (7) m 6-7wks 2014
Rusyn6 drug and metabolite quantification
with trichloroethylene
Trichloroethylene metabolite in blood, liver, kidney after trichloroethylene exposure. inbred   (7) m 6-7wks 2014
Rusyn6 RNA expression profiling
with trichloroethylene
Trichloroethylene effect on mRNA gene expression in liver and kidney, relative to controls. inbred   (7) m 6-7wks 2014
Rusyn6 histopathology
with trichloroethylene
Kidney histopathology evaluation after trichloroethylene exposure, relative to controls. inbred   (7) m 6-7wks 2014
Schauwecker1 health assessment
with pilocarpine
Study of pilocarpine effect on epilepticus seizures. inbred   (11) m 8-10wks 2012
Schwartz2 bronchoalveolar lavage assessment
with ovalbumin
Lung inflammatory changes. Ovalbumin vs. control. inbred   (8) m 6-8wks 2001
Sunde1 RNA expression profiling
with selenium
Selenium regulation of selenoprotein enzyme activity and transcripts. inbred w/CC8   (8) m 3-14wks 2018
Tarantino1 open field test
with cocaine
Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. inbred   (45) m 8-11wks 2015
Thomsen1 open field test
with cocaine
Locomotor activity. Baseline (saline) vs. cocaine i.p. (several doses). 1.3h and 2.3 h duration. inbred   (15) both 8-10wks 2011
Thomsen2 open field test
with R-6-Br-APB, quinelorane
Locomotor activity. Baseline (saline) vs. dopamine agonists i.p. (several doses). 3h session. inbred   (15) both 8-10wks 2011
Threadgill1 metabolic panel
with acetaminophen
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum), liver enzyme homeostasis. Acetaminophen (several doses) vs. control, several timepoints post-Rx. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 histopathology
with acetaminophen
Liver histopathology, necrosis after acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 metabolite quantification
with acetaminophen
Liver protein homeostasis. Acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 biomarker quantification
with acetaminophen
Liver cytochrome isoforms. Acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 organ weights
with acetaminophen
Liver weight after acetaminophen (several doses) vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill2 metabolic panel
with acetaminophen
Alanine transaminase (serum). Acetaminophen (several doses) vs. control. inbred   (5) m 6-8wks 2005
Threadgill2 metabolite quantification
with acetaminophen
Glutathione. inbred   (5) m 6-8wks 2005
Threadgill2 drug and metabolite quantification
with acetaminophen
Acetaminophen metabolite concentrations (serum) and liver protein homeostasis. Baseline vs. acetaminophen (several doses, several timepoints). inbred   (5) m 6-8wks 2005
Threadgill2 histopathology
with acetaminophen
Liver histopathology, necrosis, injury after acetaminophen vs. control. 18h fast. inbred   (5) m 6-8wks 2005
Wiltshire2 tail suspension test
with fluoxetine
Immobility. Fluoxetine-treated vs. control. 5 min test. inbred   (30) m 9-11wks 2011
Wiltshire2 open field test
with fluoxetine
Locomotor activity, exploratory and anxiety-related behavior. Fluoxetine-treated vs. control. 7 min test. inbred   (30) m 9-11wks 2011
Wiltshire2 drug and metabolite quantification
with fluoxetine
Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. inbred   (30) m 9-11wks 2011
Wiltshire3 biomarker quantification
with fluoxetine
Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. inbred   (30) m 10-11wks 2011
Wiltshire4 immune cell quantification
with BEZ235, doxorubicin, idarubicin, selumetinib
In vitro study of 4 cancer chemotherapies (BEZ235, doxorubicin, idarubicin, selumetinib) vs. control. Effect on immune cells. Normalized data. inbred w/CC7   (36) m 10wks 2015
Xenakis1 inclined screen test Latency to move all four paws. CC RIX   (73) both 7-13wks 2020
Xenakis1 open field test Locomotor activity, anxiety, stereotypy. CC RIX   (73) both 7-13wks 2020
Xenakis1 behavior observation Vacuous chewing, tongue protrusion, jaw tremor. CC RIX   (73) both 7-13wks 2020